US Army Creates Single Vaccine Against All COVID & SARS Variants
Within weeks, Walter Reed researchers expect to announce that human trials show success against Omicron—and even future strains. Within weeks, scientists at the Walter Reed Army Institute of Research expect to announce that they have developed a vaccine that is effective against COVID-19 and all its variants, even Omicron, as well as previous SARS-origin viruses that have killed millions of people worldwide. The achievement is the result of almost two years of work on the virus. The Army lab received its first DNA sequencing of the COVID-19 virus in early 2020. Very early on, Walter Reed’s infectious diseases branch decided to focus on making a vaccine that would work against not just the existing strain but all of its potential variants as well. Walter Reed’s Spike Ferritin Nanoparticle COVID-19 vaccine, or SpFN, completed animal trials earlier this year with positive results. Phase 1 of human trials, which tested the vaccine against Omicron and the other variants, wrapped up this month, again with positive results that are undergoing final review, Dr. Kayvon Modjarrad, director of Walter Reed’s infectious diseases branch, said in an exclusive interview with Defense One. The new vaccine will still need to undergo phase 2 and phase 3 trials. Unlike existing vaccines, Walter Reed’s SpFN uses a soccer ball-shaped protein with 24 faces for its vaccine, which allows scientists to attach the spikes of multiple coronavirus strains on different faces of the protein.
The Walter Reed National Military Medical Center, colloquially referred to as the Bethesda Naval Hospital, is a United States' tri-service military medical center, located in the community of Bethesda, Maryland, near the headquarters of the National Institutes of Health. It is one of the most prominent U.S. military medical centers in the Washington, D.C.metropolitan area and the United States, having served numerous U.S. presidents since the 20th century.